^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoDEEP

    Company:
    OncoDNA
    Type:
    Laboratory Developed Test
    Related tests:
    Evidence Level:
    Resistant: C4 – Case Studies

    [ARID1A mutation + MSI-H-Lung Adenocarcinoma-cisplatin + pemetrexed]

    Source:
    J Med Case Rep
    Test:

    PD-L1 IHC 22C3 pharmDx, Guardant360® CDx, OncoDEEP

    Title:
    ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report
    Published date:
    02/19/2021
    Excerpt:
    Liquid biopsy test reported actionable alterations in ARID1A gene...Genomic analysis of a sample of this metastasis confirmed PD-L1 positivity of greater than 50% with CD8+ T cells expression and showed MSI with a deleterious c.298C>T (p.R100*) MLH1 gene mutation....In December 2018, a PR was achieved with cisplatin plus pemetrexed reintroduction since October 2018 (Fig. 1), but the disease progressed shortly after. Immunotherapy rechallenge and vinorelbine did not succeed either.
    DOI:
    10.1186/s13256-020-02589-1
    Evidence Level:
    Resistant: C4 – Case Studies

    [ARID1A mutation + MSI-H-Lung Adenocarcinoma-Immunotherapy]

    Source:
    J Med Case Rep
    Test:

    PD-L1 IHC 22C3 pharmDx, Guardant360® CDx, OncoDEEP

    Title:
    ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report
    Published date:
    02/19/2021
    Excerpt:
    Liquid biopsy test reported actionable alterations in ARID1A gene...The patient was treated with immunotherapy, and showed a treatment response lasting for 19 months until a new metastasis appeared at the right deltoid muscle. Genomic analysis of a sample of this metastasis confirmed PD-L1 positivity of greater than 50% with CD8+ T cells expression and showed MSI with a deleterious c.298C>T (p.R100*) MLH1 gene mutation.
    Secondary therapy:
    vinorelbine tartrate
    DOI:
    10.1186/s13256-020-02589-1
    Evidence Level:
    Resistant: C4 – Case Studies

    [ARID1A mutation + MSI-H-Lung Adenocarcinoma-nivolumab]

    Source:
    J Med Case Rep
    Test:

    PD-L1 IHC 22C3 pharmDx, Guardant360® CDx, OncoDEEP

    Title:
    ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report
    Published date:
    02/19/2021
    Excerpt:
    Liquid biopsy test reported actionable alterations in ARID1A gene...Nivolumab 3 mg/kg intravenously every 2 weeks was administered for 38 cycles....The patient was treated with immunotherapy, and showed a treatment response lasting for 19 months until a new metastasis appeared at the right deltoid muscle. Genomic analysis of a sample of this metastasis confirmed PD-L1 positivity of greater than 50% with CD8+ T cells expression and showed MSI with a deleterious c.298C>T (p.R100*) MLH1 gene mutation.
    DOI:
    10.1186/s13256-020-02589-1